This is a working overview of incretin receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-15 and is reviewed periodically as new material appears.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Coffin separation: the body is placed into the chamber. Cryogenic freezing: liquid nitrogen at −196 °C crystallizes the body. Vibration: the body is disintegrated into particles. Freeze drying: particles are freeze dried in a drying chamber, leaving approximately 30% of the original weight. Metal separation: any metals (e.g., tooth amalgam, artificial hips, etc.) are removed, either by magnetism or by sieving. The dry powder is placed in a biodegradable casket which is interred in the top layers of soil, where aerobic bacteria decompose the remains into humus in as little as 6–12 months.
=== Adobe ColdFusion (2018 Release) === Adobe ColdFusion (2018 release), known generically as ColdFusion 2018, was released on July 12, 2018. ColdFusion 2018 was codenamed Aether during prerelease. As of March 2023, Adobe had released 16 updates for ColdFusion 2018. New or improved features available in all editions (Standard, Enterprise, and Developer) include:
The photosynthetic partners, or photobionts, of X. parietina belong to the green algal genus Trebouxia, including Trebouxia arboricola and T. irregularis. These algae also exist independently in nature, occurring on both lichen-colonized and lichen-free bark. A study found that the photobiont occupies 7% of the thallus volume in X. parietina. Pigmentation density in the upper cortex varies, regulating light exposure to the algae. The Trebouxia photobiont adjusts its photosynthetic activity seasonally, supporting X. parietina in sunlit environments. As sunlight increases in spring, the photobiont reduces chlorophyll levels and produces protective pigments to dissipate excess light as heat. Chlorophyll concentrations are lowest in spring and peak in winter, balancing light absorption and photoprotection throughout the year. X. parietina associates with diverse photobionts. It primarily partners with Trebouxia decolorans when growing on bark and with T. arboricola on rock. Even within local populations, genetically distinct photobionts often coexist in adjacent thalli. One study identified 36 algal genotypes among 38 epiphytic samples from a single site. Despite T. decolorans being assumed to reproduce asexually, multiple algal strains sometimes occur within a single thallus, suggesting photobiont switching or thallus fusion. This diversity may contribute to X. parietina's adaptability across varied environments. Although free-living algae are abundant, X. parietina selectively associates with Trebouxia species.
== Discovery == RGD was identified as the minimal recognition sequence within fibronectin required for cell attachment by Ruoslahti and Pierschbacher in the early 1980s. To do this, the authors synthesized various peptides based on the hypothesized cell attachment site of fibronectin. They then coupled those peptides to protein-coated plastic and tested each for cell attachment-promoting activity. Only those that contained the RGD sequence were found to enhance cell attachment. Further, they showed that peptides containing RGD were able to inhibit cell attachment to fibronectin-coated substrates, whereas peptides not containing RGD did not. These foundational studies also identified the cellular receptors that recognize the sequence. These studies utilized a synthetic RGD-containing peptide to isolate the putative receptors, and then demonstrated that liposomes containing the isolated proteins could bind to fibronectin, in much the same way as cells with surface receptors. The discovered receptors were later named integrins. The RGD motif is presented in slightly different ways in different proteins, making it possible for the many RGD-binding integrins to selectively distinguish individual adhesion proteins.
South of Centro stands the Crocetta district, considered one of the most exclusive districts of the city, because of highly rated residential buildings. At the heart of the district is the partially pedestrianised area crossed by Corso Trieste, Corso Trento and Corso Duca D'Aosta, plenty of some notable residential buildings in eclectic, neo-Gothic and Art Nouveau style. The area was built between 1903 and 1937 replacing the old parade ground, which was moved in the southern part of the city. North of this area stands the GAM (Galleria d'Arte Moderna), one of the two Museum of Modern Arts of the Turin Metro area (the second and largest one is hosted in Castello di Rivoli, a former Savoy royal castle in the suburbs). The museum stands in front a huge monument situated in the centre of the roundabout between Corso Vittorio Emanuele II and Corso Galileo Ferraris: the Monument to Vittorio Emanuele II, a king of Savoy statue situated on a 39-metres high column. Next to the museum, another significant residential building previously hosted the head office of Juventus, one of the two main Turin football clubs. West of this area, the main building of Polytechnic University of Turin stands along Corso Duca Degli Abruzzi. The 1958 building, a 122,000 m2 (1,313,197 sq ft) complex, hosts approximately 30,000 students and is considered one of the major institutes of technology of the country—mainly due to the vocation of the city for the industrialisation, pushed by the automotive sector.
Sources: en.wikipedia.org
=== Fatty Acid Synthesis === Fatty acid synthesis begins in the cytosol. During the first reaction, irreversible carboxylation of acetyl-CoA to malonyl-CoA is catalyzed by the biotin-dependent enzyme acetyl-CoA carboxylase (ACC). Notably, the conversion of acetyl-CoA to malonyl-CoA is the rate-limiting step of fatty acid synthesis. Acetyl-CoA carboxylase (ACC) thus represents the rate-limiting enzyme in fatty acid synthesis; ACC activity is stimulated by increasing concentrations of cytosolic citrate, and inhibited by increasing concentrations of the fatty acid palmitate. After malonyl-CoA becomes available by virtue of ACC, fatty acid synthase (FAS) is then able to complete a series of reactions to form the 16-carbon molecule palmitate. FAS is a complex, multifunctional protein containing seven different catalytic sites: acetyl transacylase, malonyl transacylase, β-ketoacyl synthase, β-ketoacyl carrier protein (ACP) reductase, 3-hydroxyacyl-ACP dehydratase, enoyl-ACP reductase, and thioesterase. These different enzymes are covalently linked within the FAS complex, allowing for intermediates to be handled efficiently from one active site to another without leaving the assembly. After the completion of the first reaction by ACC, fatty acid synthesis thus continues on the FAS complex. During the second reaction of fatty acid synthesis, acetyl transacylase and malonyl transacylase catalyze the formation of acetyl-ACP and malonyl-ACP, respectively.
Penicillamine, which contains nitrogen and sulphur donor atoms, is used as this type of ligand binds more strongly to copper ions than to calcium and magnesium ions. Treatment of poisoning by heavy metals such as lead and mercury is more problematical, because the ligands used do not have high specificity relative to calcium. For example, EDTA may be administered as a calcium salt to reduce the removal of calcium from bone together with the heavy metal. Factors determining selectivity for lead against zinc, cadmium and calcium have been reviewed.
The most common mechanism of stimulation of acupuncture points employs penetration of the skin by thin metal needles, which are manipulated manually or the needle may be further stimulated by electrical stimulation (electroacupuncture). Acupuncture needles are typically made of stainless steel, making them flexible and preventing them from rusting or breaking. Needles are usually disposed of after each use to prevent contamination. Reusable needles when used should be sterilized between applications. In many areas, only sterile, single-use acupuncture needles are allowed, including the State of California. Needles vary in length between 13 and 130 millimetres (0.51 and 5.12 in), with shorter needles used near the face and eyes, and longer needles in areas with thicker tissues; needle diameters vary from 0.16 mm (0.006 in) to 0.46 mm (0.018 in), with thicker needles used on more robust patients. Thinner needles may be flexible and require tubes for insertion. The tip of the needle should not be made too sharp to prevent breakage, although blunt needles cause more pain. Apart from the usual filiform needle, other needle types include three-edged needles and the Nine Ancient Needles. Japanese acupuncturists use extremely thin needles that are used superficially, sometimes without penetrating the skin, and surrounded by a guide tube (a 17th-century invention adopted in China and the West). Korean acupuncture uses copper needles and has a greater focus on the hand.
=== Somalia === In Somalia, frankincense is harvested in the Bari and Sanaag regions: mountains lying at the northwest of Erigavo; El Afweyn District; Cal Madow mountain range, a westerly escarpment that runs parallel to the coast; Cal Miskeed, including Hantaara and Habeeno plateau and a middle segment of the frankincense-growing escarpment; Karkaar mountains or eastern escarpment, which lies at the eastern fringe of the frankincense escarpment.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.